13D
|
|
|
CUSIP No. 45332Y109
|
|
Page 8 of 10 Pages
|
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:
Between August 27, 2021 and September 7, 2021, Gilde Healthcare sold an aggregate of 848,145 shares of Common Stock of the Issuer in open market
transactions as set forth on Annex A to this Schedule 13D.
Item 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and restated in its entirety below:
(a)
According to the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 10, 2021, there were 49,928,519 shares of Common Stock
outstanding as of August 6, 2021.
Gilde Healthcare is the record holder of an aggregate of 2,400,612 shares of Common Stock, which represents
beneficial ownership of approximately 4.8% of the outstanding shares of Common Stock reported as of August 6, 2021.
GHCIVM, as the manager of Gilde
Healthcare, has the power to vote and dispose of securities held by Gilde Healthcare and may be deemed to beneficially own the securities held of record by Gilde Healthcare.
As a result, each of the Reporting Persons may beneficially own an aggregate of 2,400,612 shares of Common Stock, or approximately 4.8% of the outstanding
Common Stock.
(b) Each Reporting Person has shared power to vote and dispose of 2,400,612 shares of Common Stock.
(c) Except as reported on Annex A, none of the Reporting Persons has effected any transactions in the Issuers securities within the past
60 days.
(d) Only Gilde Healthcare has the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by Gilde
Healthcare.
(e) As a result of the sales described herein, the Reporting Persons ceased to be the beneficial owner of more than 5% of the Issuers
Common Stock. The filing of this Amendment No. 6 represents the final amendment to this Schedule 13D and constitutes an exit filing for the Reporting Persons.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer.
Except as referenced herein, there are no changes to the Item 6 information previously filed.